Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
Hattori M, Masuda N, Takano T, Tsugawa K, Inoue K, Matsumoto K, Ishikawa T, Itoh M, Yasojima H, Tanabe Y, Yamamoto K, Suzuki M, Pan W, Cortes J, Iwata H. Hattori M, et al. Among authors: inoue k. Cancer Med. 2023 May;12(9):10280-10293. doi: 10.1002/cam4.5757. Epub 2023 Mar 14. Cancer Med. 2023. PMID: 36916728 Free PMC article. Clinical Trial.
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S. Inoue K, et al. Breast Cancer Res Treat. 2010 Jan;119(1):127-36. doi: 10.1007/s10549-009-0498-7. Epub 2009 Aug 19. Breast Cancer Res Treat. 2010. PMID: 19690954 Clinical Trial.
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Aogi K, Sakai H, Yoshizawa H, Masuda N, Katakami N, Yanagita Y, Inoue K, Kuranami M, Mizutani M, Masuda N. Aogi K, et al. Among authors: inoue k. Support Care Cancer. 2012 Jul;20(7):1507-14. doi: 10.1007/s00520-011-1239-0. Epub 2011 Aug 2. Support Care Cancer. 2012. PMID: 21808994 Clinical Trial.
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Shien T, Nakamura K, Shibata T, Kinoshita T, Aogi K, Fujisawa T, Masuda N, Inoue K, Fukuda H, Iwata H. Shien T, et al. Among authors: inoue k. Jpn J Clin Oncol. 2012 Oct;42(10):970-3. doi: 10.1093/jjco/hys120. Epub 2012 Jul 24. Jpn J Clin Oncol. 2012. PMID: 22833684 Clinical Trial.
Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).
Shien T, Iwata H, Aogi K, Fukutomi T, Inoue K, Kinoshita T, Takahashi M, Matsui A, Shibata T, Fukuda H. Shien T, et al. Among authors: inoue k. Int J Clin Oncol. 2014 Dec;19(6):982-8. doi: 10.1007/s10147-013-0657-z. Epub 2014 Jan 7. Int J Clin Oncol. 2014. PMID: 24395447 Clinical Trial.
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y. Ando M, et al. Among authors: inoue k. Breast Cancer Res Treat. 2014 Jun;145(2):401-9. doi: 10.1007/s10549-014-2947-1. Epub 2014 Apr 12. Breast Cancer Res Treat. 2014. PMID: 24728578 Clinical Trial.
Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404.
Shien T, Iwata H, Fukutomi T, Inoue K, Aogi K, Kinoshita T, Ando J, Takashima S, Nakamura K, Shibata T, Fukuda H. Shien T, et al. Among authors: inoue k. Cancer Chemother Pharmacol. 2014 Sep;74(3):603-9. doi: 10.1007/s00280-014-2545-2. Epub 2014 Jul 24. Cancer Chemother Pharmacol. 2014. PMID: 25055938 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Inoue K, Kuroi K, Shimizu S, Rai Y, Aogi K, Masuda N, Nakayama T, Iwata H, Nishimura Y, Armour A, Sasaki Y. Inoue K, et al. Int J Clin Oncol. 2015 Dec;20(6):1102-9. doi: 10.1007/s10147-015-0832-5. Epub 2015 May 13. Int J Clin Oncol. 2015. PMID: 25967286 Free PMC article. Clinical Trial.
9,840 results